As of the October 26, 2026 close of $444.63, AMGN rose 1.22% on 2.04 million shares, only 0.75x its 20-day average of 2.71 million and 0.70x its 60-day average of 2.94 million, and still sits 1.41% below the October 22 52-week high of $450.98, so the October 22 breakout remains a retest rather than a confirmed extension. The macro tape firmed: the fell 5.45% to 18.39 from 19.45, the 10-year Treasury eased to 4.986% from 4.988%, and the S&P 500 (+0.70%), Nasdaq (+0.82%) and Dow (+0.28%) all advanced, leaving the Neutral regime at its more constructive end while a 10-year yield pinned near 5% still caps multiple expansion on long-duration pharma cash flows. The technical structure is constructive: price is 5.20% above the $422.64 , 7.53% above the $413.49 and 19.08% above the $373.39 , with the 10.74% above a rising in an intact golden-cross alignment; advanced to 9.43 versus a 6.83 signal even as the histogram narrowed to 2.60 from 2.75, recovered to 63.17 from 60.86, and rebuilt to 69.40 million from 67.36 million but is still roughly 9.6% below its September 29 peak of 76.74 million while price is 4.96% above that day's $423.64 close, so volume is lagging rather than confirming. Fundamentals remain a high-quality but low-growth package: 71.89% gross margin, 35.55% operating margin, 45.33% margin and $8.65 billion of free cash flow against roughly 9.5% Q2 2026 revenue growth that is being partly consumed by Prolia -32% to $759 million and Xgeva -34% to $352 million on biosimilars. Valuation is the binding constraint: 27.62x trailing and 18.15x forward earnings on $24.49175 of next-year consensus versus $23.03434 for the current year, implying only about 6.3% growth, for a 2.62 and 16.26x . The $397.32 mean target now sits 10.6% below spot and the $405 median 8.9% below it, while the $500 high is only 12.45% above and the $225 low is 49.4% below, an unusually wide band that captures genuine disagreement about whether dazodalibep, MariTide and the I&I pipeline can replace legacy cash flows. Estimate revisions remain split by horizon, with next-year 4.46% above its 90-day-ago level and seven upward versus one downward revision in 30 days, while current-quarter and current-year numbers drifted slightly lower with three down versus two up in the last seven days and the Buy count slipping from 10 to 8 as Sell ratings rose from 2 to 3 over two months. News flow is still constructive around the September 22 OASIZ 301 win for dazodalibep in systemic Sjogren's, $3.5 billion of Q2 free cash flow, Oppenheimer's October 23 raise to $480 from $450 and Barclays' October 21 raise to $400 from $380, but full efficacy and safety detail are withheld, OASIZ 303 is still pending in Q4 2026, and Roche's enicepatide (15.5% average weight loss at 24 mg) raises the competitive bar for MariTide. The binding near-term constraint is the November 3 Q3 report, now just 7 calendar days away, with at 2.38% of price implying a $10-$11 daily range and realistic overnight gap risk above $20. The HOLD reflects an intact uptrend, a durable franchise and improving cash generation balanced against an extended growth-adjusted multiple, a price 10.6% above the mean analyst target, unconfirmed volume and binary event risk no price-based stop can contain; the key levels to monitor are $439.50 and $437.19 into the print, then $432.49 and the $424.74/$422.64 shelf.
Decision
Live price
$444.63
Recommendation score
57%
57%
Confidence
60%
60%
Outlook by horizon
1M
HOLD
Near
6M
HOLD
Mid
1Y
HOLD
Long
Primary catalyst
The November 3 Q3 earnings report, now 7 calendar days away, is the dominant near-term market mover: with at 2.38% of price and 28.12% realized volatility, a single-session gap can plausibly exceed $20 and bypass any price-based stop. The September 22 OASIZ 301 win for dazodalibep remains the most consequential company-specific item because it de-risks a late-stage asset in an indication with no approved US therapy, but withheld efficacy detail and the pending OASIZ 303 readout leave its commercial value unquantified.
Limit exposure to roughly 50% of normal size into the November 3 report and the undated Q4 OASIZ 303 readout, or wait for post-event confirmation. at 18.39 is at the upper end of the Neutral band and the $1.15 billion 20-day average dollar volume allows full-size execution, but 28.12% realized volatility, 2.38% , a price 1.41% below the 52-week high but 10.6% above the mean analyst target, and four sessions of narrowing histogram argue against chasing into the print; avoid leverage.
Thesis Snapshot
Why It Works
The strongest case for owning Amgen is that a durable, high-margin, cash-generative franchise is simultaneously producing credible replacement growth, de-risking its late-stage pipeline, and still sitting in an intact uptrend above every major moving average. Q2 revenue rose about 9.5% with operating cash flow of $12.48 billion, free cash flow of $8.65 billion and a 3.60% FCF yield, four growth products advanced strongly, all six supplied quarters beat consensus by an average of roughly 12.4%, and dazodalibep cleared OASIZ 301 in an indication with no approved US therapy. Next-year estimates are 4.46% above their level 90 days ago with seven upward versus one downward revision in the last 30 days, Oppenheimer raised its target to $480 on October 23, and price is 19.08% above a rising with still advancing to 9.43. The October 26 session added $5.37 versus the October 23 close, lifting the stock toward the $447.28-$450.98 resistance shelf, and the prior $432-$442 entry zone is now below spot, so the setup has shifted from buying the retest to waiting for a second retest or paying up post-earnings; a decisive close above $450.98 on heavier than average volume would validate a run at the $465-$480 exit zone, aided by a that eased 5.45% to 18.39 and a 10-year yield that stopped rising at 4.986%.
What Breaks It
The strongest argument against owning Amgen here is that the market has now paid for flawless execution and then some. At 18.15x forward earnings against only about 6.3% consensus next-year growth ( 2.62, or roughly 2.87x on forward divided by growth) and of 16.26x, the stock closed 10.6% above the $397.32 mean analyst target while Prolia falls 32% and Xgeva 34% on biosimilars, Enbrel faces Medicare Part D price setting, and $43.31 billion of net debt against 490.28% debt-to-equity limits flexibility. Third-party work cited in the news flow puts a multiples-based fair value near $359.98, roughly 19% below spot, the Buy count has slipped from 10 to 8 and Sell ratings from 2 to 3 over two months, and three of the last five target actions were cuts. The October 26 rebound is unconvincing: volume of 2.04 million was only 0.75x the 20-day average, the close of $444.63 remained below both the $447.28 October 22 close and the $450.98 high, the histogram narrowed for a fourth straight session to 2.60, and at 69.40 million is still roughly 9.6% below its September 29 peak even though price is 4.96% above that day's close. With at 63.17 and earnings 7 days out, the short thesis is that legacy erosion outpaces replacement growth, that the September pipeline win is fully capitalized, and that a soft Prolia guide on November 3 forces estimate cuts and multiple compression; short interest at 2.60% of float with a 4.45 short ratio is not crowded, so there is limited forced-covering support if the print disappoints.
A daily close below $437.19 (the October 22 low) would flag the new-high breakout as a failed move, and confirmation below the $424.74 October 19 low and the $422.64 would break the higher-low sequence and require exit or full reassessment; on the fundamental side, the equivalent signal would be a November 3 guide-down on Prolia or deceleration of the growth-driver cohort below roughly 20% combined.
Legacy erosion: Q2 Prolia fell 32% to $759 million and Xgeva 34% to $352 million on biosimilars from Prolia's $4.41 billion 2025 base, with management guiding a faster 2026 decline; if replacement products decelerate, the approximately 6.3% consensus next-year growth is at risk.
Valuation and target compression: 18.15x forward earnings and a 2.62 against about 6.3% growth, with the $397.32 mean target 10.6% below the $444.63 close, the $405 median 8.9% below, and three target cuts in the last two weeks (BMO to $415 from $450, Guggenheim to $378 from $388, Wells Fargo to $430 from $435).
Balance sheet and rate sensitivity: $43.31 billion of net debt, 490.28% debt-to-equity, cash covering only 0.24x debt and operating cash flow 0.22x, with the 10-year at 4.986% still roughly 270 basis points above the 2.29% dividend yield.
Clinical and competitive risk: full OASIZ 301 efficacy and safety data are undisclosed, OASIZ 303 is required in Q4 2026 with no date, Novartis' ianalumab competes in Sjogren's, and Roche's enicepatide (15.5% weight loss at the top dose with about 2% discontinuation) raises the bar for MariTide in obesity.
Event and trading risk: Q3 earnings on November 3 is 7 days away, 20-day realized volatility is 28.12% and is 2.38% of price, so an overnight gap can exceed the $421 stop; the October 26 1.22% gain also came on only 0.75x average volume with the close still below the $450.98 high, meaning the breakout remains unconfirmed and depends on a volume-backed follow-through that has not yet appeared.
Watch Next
Next earnings: Nov 3, 2026
The November 3 Q3 earnings report, now 7 calendar days away, is the dominant near-term market mover: with at 2.38% of price and 28.12% realized volatility, a single-session gap can plausibly exceed $20 and bypass any price-based stop. The September 22 OASIZ 301 win for dazodalibep remains the most consequential company-specific item because it de-risks a late-stage asset in an indication with no approved US therapy, but withheld efficacy detail and the pending OASIZ 303 readout leave its commercial value unquantified.
Signal Dashboard
Decision inputs
6 signals
Fundamental
-10.6%
Upside to analyst mean target
At $444.63, AMGN trades at 27.62x trailing and 18.15x forward earnings on $24.49175 of next-year consensus versus $23.03434 for the current year, implying only about 6.3% growth; dividing that 18.15x forward multiple by the 6.3% growth rate yields roughly 2.87x, and the supplied of 2.62 is well above a 1.5x growth benchmark either way. is 16.26x, price-to-sales is 6.31x against 9.5% revenue growth, price-to-book is 20.57x and enterprise value of $280.79 billion is 1.17x the $240.38 billion market capitalization. The 3.60% free-cash-flow yield is genuine support but remains 139 basis points below the 4.986% 10-year Treasury yield, so it does not compensate for equity risk on its own. The $397.32 mean target implies 10.6% downside and the $405 median implies 8.9% downside, while the $500 high is only 12.45% above spot and the $225 low is 49.4% below, a spread that captures real disagreement over whether the pipeline can replace Prolia, Xgeva and Enbrel cash flows. No peer or historical multiple series is supplied, so relative cheapness cannot be established; on absolute growth-adjusted terms the stock screens expensive even after pulling back 1.41% from the $450.98 high.
Technical
Bullish
Trend quality
At $444.63, price is 5.20% above the $422.64 , 7.53% above the $413.49 and 19.08% above the $373.39 . The sits 10.74% above a rising , an established golden-cross alignment rather than one still forming, so the primary uptrend is intact. The short-term issue remains the October 22 breakout candle: the stock printed a 52-week high of $450.98 and closed at $447.28 above the prior $447.03 high, then on October 23 opened at $444.40, failed at $444.59 and closed at $439.26 near the session low. October 26 partially repaired that with a 1.22% advance to $444.63 on a $439.50-$449.80 range, but the close was still below both the $447.28 prior close and the $450.98 high, so the breakout remains in retest rather than confirmation. The higher-low sequence off the September 15 low of $375.15 remains intact while $437.19 and $424.74 hold.
Earnings
7d
Steady
Q2 2026 of $6.29 beat the $5.6176 consensus by 11.97% on revenue of about $10.1 billion (+9.5% year over year) with roughly $3.5 billion of quarterly free cash flow; the immediate post-report price reaction is not contained in the bundle, and the widely cited roughly 4% single-day gain in the news flow is attributed to the September 22 OASIZ 301 announcement rather than to earnings.
News
Mixed-Bullish
Headline tone
The November 3 Q3 earnings report, now 7 calendar days away, is the dominant near-term market mover: with at 2.38% of price and 28.12% realized volatility, a single-session gap can plausibly exceed $20 and bypass any price-based stop. The September 22 OASIZ 301 win for dazodalibep remains the most consequential company-specific item because it de-risks a late-stage asset in an indication with no approved US therapy, but withheld efficacy detail and the pending OASIZ 303 readout leave its commercial value unquantified.
Macro
Neutral
4.99% 10Y / 18.4 VIX
easing 5.45% to 18.39 alongside a 10-year at 4.986% gives a marginally friendlier tape for long-duration pharma cash flows, but with the yield essentially pinned near 5% and Amgen's 2.29% dividend yield roughly 270 basis points below the risk-free rate, multiple expansion still has to be earned by earnings and pipeline evidence rather than by macro help.
Stability
Balanced Growth
Core Growth
Amgen is a high-margin, cash-generative large-cap pharmaceutical franchise with a 71.89% gross margin, a 35.55% operating margin, $12.48 billion of operating cash flow, $8.65 billion of free cash flow (a 3.60% FCF yield) and a 2.29% dividend, which earns it a growth-sleeve slot rather than a tactical trading slot. What caps the quality of that compounding is accelerating Prolia (-32% to $759 million) and Xgeva (-34% to $352 million) biosimilar erosion, $43.31 billion of net debt against a 490.28% debt-to-equity ratio, and an 18.15x forward multiple on only about 6.3% consensus next-year growth for a 2.62 . The reported 0.407 beta materially understates risk: 20-day realized volatility is 28.12%, is 2.38% of price ($10.58), and there is binary gap risk around the November 3 earnings report plus the undated Q4 2026 OASIZ 303 readout. That combination belongs in a Core Growth bucket sized for high drawdown potential, not in a low-volatility Core Anchor slot.
Analyst Spread
Mean Target
$397.32
High / Low
$225 / $500
Median Target
$405.00
Consensus range
$225 - $500
— analysts
Mean
$225$397$500
Consensus
The ratings tally sums to 34 opinions (4 Strong Buy, 8 Buy, 17 Hold, 3 Sell, 2 Strong Sell) and is unchanged from one month earlier, so the sell-side posture is stable but still skewed to Hold even after the run to $450.98. The explicit analyst-count field is null, so coverage breadth is inferred from the tally. The mean target of $397.32 sits 10.6% below the $444.63 close and the $405 median sits 8.9% below it, meaning the stock has run past the average analyst's fair value; the $500 high is only 12.45% above spot while the $225 low is 49.4% below, a band that captures genuine disagreement about the durability of the replacement-pipeline thesis. The October 23 Oppenheimer raise to $480 is the most recent and highest-profile action and shows at least one bull sees further upside, but it has not moved the mean above spot.
Positioning Pulse
Insider Signal
Neutral
Net Bias
No recent activity
Insider Own.
0.2%
Institutional Own.
85.2%
Interpretation
There is no classifiable recent discretionary insider activity in the bundle, so insider behavior provides no reliable signal about management's near-term confidence and should not influence the rating.
Notable activity
The only supplied record lists CTO David M. Reese with 33,936 directly held shares valued at $10.23 million, but its date field is the malformed value 99 and its transaction type is blank, so it cannot be classified as an open-market purchase, a discretionary sale, an option exercise or a pre-scheduled 10b5-1 trade.
Market Context
Industry
Drug Manufacturers - General
Mixed-Bullish
Sentiment
24
Tracked names
5
Grouping
industry
Drug Manufacturers - General industry is currently Mixed-Bullish with an average recommendation score near 60. capital and conviction are improving across the group, and leadership is concentrated in LLY, JNJ, ABBV.
Rotation Drivers
Average recommendation deltas are trending higher across Drug Manufacturers - General industry, which suggests improving risk appetite inside the group.
2 names are rated bullish versus 0 bearish names, keeping the group tone mixed-bullish.
Leadership is concentrated in LLY, JNJ, ABBV, so those names are the cleanest read on group-level capital rotation.
Capital is being re-directed toward large-cap pharma stories with late-stage immunology optionality, and Amgen now sits in that bucket after dazodalibep cleared OASIZ 301 in systemic Sjogren's, an indication with no approved US therapy. Commercial support exists inside the same franchise, with Tezspire up 42% to $486 million and Uplizna up 90% to $335 million in Q2, but full OASIZ 301 efficacy and safety data have not been disclosed and Novartis' ianalumab is a direct competitor. The theme is strengthening modestly rather than fully confirmed; the bundle contains no fund-flow data, so the rotation read rests on price momentum and news flow rather than measured flows, and the October 23 reversal followed by only a partial October 26 rebound shows the theme premium is not being defended aggressively ahead of earnings.
OASIZ 303, the second pivotal study likely required for a filing, is expected in Q4 2026 with no precise date, and the stock has tested a 52-week high of $450.98 into that catalyst window with next-year estimates 4.46% above their 90-day-ago level.
Dazodalibep met the OASIZ 301 primary endpoint with clinically meaningful improvement in disease activity and few discontinuations, prompting a roughly 4% single-day move and subsequent target raises from Oppenheimer to $480 and Barclays to $400.
Q2 Tezspire and Uplizna sales grew 42% and 90% respectively while Prolia and Xgeva fell 32% and 34%, shifting portfolio mix and narrative weight toward newer immunology assets.
Relative-strength signal: AMGN rose 2.04% on October 22 while the Nasdaq fell 2.60%, but it gave back 1.79% on October 23 before recovering 1.22% on October 26, indicating the defensive-rotation bid is intermittent rather than a sustained theme inflow.
Obesity / GLP-1 Competitive Race
Score: -25
Mixed-Bearish
The obesity opportunity is expected to exceed $100 billion in annual sales within a decade and is attracting continuous clinical news flow, but for Amgen the theme currently reads as competitive pressure rather than upside. Roche's enicepatide delivered 15.5% average weight loss at the highest dose in a 447-patient mid-stage type 2 diabetes study, with late-stage glycemic and cardiovascular outcomes studies planned for the first half of 2027, while Amgen's MariTide remains pre-commercial and lacks the domestic GLP-1 manufacturing scale that Eli Lilly and Novo Nordisk already command. The theme weakens Amgen's relative narrative positioning until MariTide produces differentiating data.
Roche's September 28 enicepatide update adds a fresh, credible challenger to a field where the incumbents already hold fast-track approvals, sharpening the execution bar for Amgen's obesity program while the regulatory CNPV pathway it might rely on faces durability questions.
Roche reported 15.5% average weight loss at the 24 mg dose with about 62% of patients reaching HbA1c below 5.7% and only around 2% discontinuation from side effects, a competitive tolerability read that met both primary goals.
News-flow supply chain analysis argues Amgen lacks the massive domestic GLP-1 manufacturing infrastructure held by Eli Lilly and Novo Nordisk, so even a fast regulatory path would not translate quickly into share.
Key Stats
23 metrics total
Market Cap
$240.38B
P/E (TTM)
27.6
Forward P/E
18.2
Revenue Growth
9.5%
ROE
91.5%
Beta
0.41
Full Metric Set
17 additional stats
Valuation Stack
Multiples and cash-flow framing.
Price / Sales
6.3
Price / Book
20.6
EV / EBITDA
16.3
Quality & Balance Sheet
Margins, leverage, and liquidity.
Gross Margin
71.9%
Operating Margin
35.5%
Debt / Equity
490.3
Current Ratio
1.37x
Quick Ratio
0.95x
Positioning & Range
Short interest and 52-week location.
Short % Float
2.6%
Short Ratio
4.45x
52W High
$450.98
52W Low
$288.00
From 52W High
-1.4%
From 52W Low
54.4%
Company Classification
Sector and industry context.
Sector
Healthcare
Industry
Drug Manufacturers - General
Additional Signals
Free Cash Flow
$8645624832.00
Detailed Analysis
Valuation
At $444.63, AMGN trades at 27.62x trailing and 18.15x forward earnings on $24.49175 of next-year consensus versus $23.03434 for the current year, implying only about 6.3% growth; dividing that 18.15x forward multiple by the 6.3% growth rate yields roughly 2.87x, and the supplied of 2.62 is well above a 1.5x growth benchmark either way. is 16.26x, price-to-sales is 6.31x against 9.5% revenue growth, price-to-book is 20.57x and enterprise value of $280.79 billion is 1.17x the $240.38 billion market capitalization. The 3.60% free-cash-flow yield is genuine support but remains 139 basis points below the 4.986% 10-year Treasury yield, so it does not compensate for equity risk on its own. The $397.32 mean target implies 10.6% downside and the $405 median implies 8.9% downside, while the $500 high is only 12.45% above spot and the $225 low is 49.4% below, a spread that captures real disagreement over whether the pipeline can replace Prolia, Xgeva and Enbrel cash flows. No peer or historical multiple series is supplied, so relative cheapness cannot be established; on absolute growth-adjusted terms the stock screens expensive even after pulling back 1.41% from the $450.98 high.
Balance Sheet
Leverage remains the weakest link. Total debt of $57.30 billion against $13.99 billion of cash leaves $43.31 billion of net debt, equal to 18.02% of market capitalization, with debt-to-equity at 490.28%. Cash covers only 0.24x debt and operating cash flow covers 0.22x, so the balance sheet depends on continuous refinancing, and a 10-year yield near 4.99% keeps that cost elevated. The offsets are real: operating cash flow of $12.48 billion, free cash flow of $8.65 billion, roughly 69.3% cash conversion, and a 60.87% payout ratio that leaves the 2.29% dividend covered roughly 1.6x by earnings. of 91.47% is a leverage artifact; of 8.67% is the honest measure of asset returns. Current and quick ratios of 1.37 and 0.95 indicate adequate but not abundant liquidity.
Growth
Q2 2026 revenue rose about 9.5% year over year to roughly $10.1 billion. Growth drivers advanced strongly, led by Imdelltra +115% to $288 million, Uplizna +90% to $335 million, Tezspire +42% to $486 million and Repatha +37% to $953 million, with Otezla contributing $2.27 billion in 2025. That is being partly consumed by biosimilar and pricing pressure: Prolia fell 32% to $759 million, Xgeva fell 34% to $352 million and Enbrel fell 4% to $580 million on Medicare Part D price setting, and management has guided Prolia (2025 sales of $4.41 billion) to decline more rapidly in 2026 as US patents expire. Q2 of $6.29 versus $6.02 a year earlier is about 4.5% growth, and the consensus current-year to next-year step is only about 6.3%. The 64.9% reported earnings-growth figure is a base-effect artifact and should not be extrapolated as a forward run rate. No margin time series is supplied, so sustained expansion versus compression cannot be proven either way.
Business Quality
Amgen's economics remain those of a top-tier pharmaceutical franchise: 71.89% gross margin, 35.55% operating margin, 45.33% margin and 22.95% net margin. The franchise supports premium multiples on quality grounds, but growth rather than profitability is the constraint. of 8.67% is respectable for a capital-intensive manufacturer while the 91.47% is leverage-driven. Liquidity is adequate at a 1.37 current ratio but thin at a 0.95 quick ratio. Institutional ownership of 85.18% and insider ownership of 0.23% mean institutional positioning, not insider alignment, will drive trading behavior, and the low float differential (540.63 million shares outstanding versus 539.16 million float) leaves no structural supply overhang. The 0.407 reported beta should not be read as low risk given 28.12% realized 20-day volatility and repeated binary clinical and earnings events.
Capital Allocation
Operating cash flow of $12.48 billion and free cash flow of $8.65 billion fund roughly $7.3 billion of 2025 R&D, the dividend, and debt service. The dividend (2.29% yield, 60.87% payout) looks sustainable from both earnings and cash flow. With $43.31 billion of net debt and the 10-year near 5%, incremental capital should lean toward deleveraging and pipeline funding rather than aggressive buybacks; the $151 million Deerfield campus sale-and-leaseback reported in the news flow is consistent with a mildly asset-light posture. Share-count and buyback history are not supplied beyond the outstanding and float figures above, so no buyback-driven per-share accretion is assumed.
Estimate Revisions
Revisions are split by horizon and the split matters. Next-year of $24.49175 is 4.46% above its 90-day-ago level of $23.44701, 0.17% above its 30-day-ago level of $24.44897 and essentially flat versus its 7-day-ago level of $24.49536, with seven upward versus one downward revision over 30 days and four up versus one down in the last seven days. Current-year of $23.03434 is 3.15% above its 90-day-ago level of $22.33131 but marginally below its 30-day-ago level of $23.05565, with three up and three down over 30 days and two up versus three down in the last seven days. The near quarters are softer: current-quarter of $5.78759 is 0.11% above its 30-day-ago level of $5.78099 but was revised two up versus three down in the last seven days, and next-quarter of $5.77097 is about 0.54% below its 30-day-ago level of $5.80226 with four up and one down over 30 days. There were zero upgrades and zero downgrades in the 90-day feed, but the rating mix drifted from 4 Strong Buy, 10 Buy, 16 Hold, 2 Sell and 2 Strong Sell two months ago to 4 Strong Buy, 8 Buy, 17 Hold, 3 Sell and 2 Strong Sell now. The most recent target actions were constructive, with Oppenheimer raising to $480 from $450 on October 23 and Barclays to $400 from $380 on October 21, while Guggenheim cut to $378 from $388, BMO to $415 from $450 and Wells Fargo to $430 from $435 earlier in October.